Commentary on use of PPIs and aspirin to prevent EAC

A thoughtful commentary on the strengths and weakness of the recent clinical trial of PPI and aspirin.

Nat Rev Clin Oncol. 2018 Dec;15(12):728-730. doi: 10.1038/s41571-018-0096-x.

Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin.

Husain NS1,2, El-Serag HB3,4.

Chemoprevention for patients with Barrett’s oesophagus remains a
controversial topic. Results of the first randomized trial of chemoprevention
using a proton pump inhibitor with or without aspirin were recently reported.
We highlight strengths and weaknesses in the design of the trial and discuss
the clinical implications of the findings.

This website contains a curated and opinionated look at recent literature regarding the epidemiology and prevention of esophageal cancer, with an emphasis on esophageal adenocarcinoma. It is developed by Thomas L Vaughan MD, MPH, who can be reached with questions or suggestions through email or his research website.
©2021 Thomas L Vaughan
This website should not be considered, or used as a substitute for, medical advice, diagnosis or treatment. This site does not constitute the practice of any medical or other professional health care advice, diagnosis or treatment. The information on this website represent the views solely of Dr. Vaughan.
Cookies are used to quantify website use for resource planning.  Complete IP addresses are not collected (i.e., will be  recorded as 203.0.113.??) Feel free to opt out of cookies using add-ins of your choice without affecting website function.  No user information is collected by the risk calculator (IC-RISC).